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ABSTRACT
Encouraging results from recent clinical trials are revitalizing the field of oncolytic 
virotherapies. Human adenovirus type 5 (HAdV-C5/Ad5) is a common vector for its 
ease of manipulation, high production titers and capacity to transduce multiple cell 
types. However, effective clinical applications are hindered by poor tumor-selectivity 
and vector neutralization. We generated Ad5/kn48 by pseudotyping Ad5 with the 
fiber knob domain from the less seroprevalent HAdV-D48 (Ad48). The vector was 
shown to utilize coxsackie and adenovirus receptor (CAR) but not CD46 for cell entry. 
A 20-amino acid peptide NAVPNLRGDLQVLAQKVART (A20) was inserted into the Ad5.
Luc HI loop (Ad5.HI.A20) and Ad5/kn48 DG loop (Ad5/kn48.DG.A20) to target a 
prognostic cancer cell marker, avβ6 integrin. Relative to the Ad5.Luc parent vector, 
Ad5.HI.A20, Ad5.KO1.HI.A20 (KO1, ablated CAR-binding) and Ad5/kn48.DG.A20 
showed ~ 160-, 270- and 180-fold increased transduction in BT-20 breast carcinoma 
cells (avβ6high). Primary human epithelial ovarian cancer (EOC) cultures derived 
from clinical ascites provided a useful ex vivo model for intraperitoneal virotherapy. 
Ad5.HI.A20, Ad5.KO1.HI.A20 and Ad5/kn48.DG.A20 transduction was ~ 70-, 60- 
and 16-fold increased relative to Ad5.Luc in EOC cells (avβ6high), respectively. A20 
vectors transduced EOC cells at up to ~ 950-fold higher efficiency in the presence 
of neutralizing ovarian ascites, as compared to Ad5.Luc. Efficient transduction and 
enhanced cancer-selectivity via a non-native avβ6-mediated route was demonstrated, 
even in the presence of pre-existing anti-Ad5 immunity. Consequently, avβ6-targeted 
Ad vectors may represent a promising platform for local intraperitoneal treatment of 
ovarian cancer metastases.
INTRODUCTION
Ovarian cancer remains the sixth most common 
cancer in women, accounting for approximately 150 000 
annual deaths worldwide [1]. Many patients present with 
advanced disease and despite good initial responses to 
systemic chemotherapy, aggressive, platinum-resistant 
tumors rapidly develop. Despite the introduction of 
new drugs, there has been little improvement in overall 
survival over the past 20 years. An urgent need for new 
treatments to combat recurrent disease persists. Oncolytic 
viruses, engineered to selectively infect and lyse cancer 
cells, hold great promise in this setting and can be coupled 
with concurrent expression of high levels of therapeutic 
transgenes. Achieving local high-level replication, 
amplification and tumor cell lysis, together with the 
stimulation of anti-tumor immune responses, offers 
selectivity and power unmatched by other anti-cancer 
therapies.
Human adenoviruses (HAdV/Ad), particularly species 
C type 5 (HAdV-C5/Ad5), have found favor as agents for 
virotherapy. They efficiently transduce a wide range of 
dividing or non-dividing cell types, are easy to genetically 
engineer and can be propagated to extremely high titers 
(> 1013 viral particles/mL, vp/mL). The mechanisms 
underpinning Ad5 cellular uptake and tropism in vitro 
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are well-studied and clearly understood (reviewed in [2]). 
Cellular uptake occurs via binding of the Ad5 fiber protein to 
coxsackie and adenovirus receptor (CAR) [3]. Internalization 
involves a secondary, endocytosis-stimulating binding 
between the Ad5 penton base protein – via the conserved 
Arg-Gly-Asp (RGD) motif [4] – and αvβ3/5 integrins [5] 
on the host cell surface. CAR is ubiquitously expressed 
across human tissues, including erythrocytes [6–8] and on 
a variety of tumor cells, although a number of reports have 
associated tumor progression with loss of CAR expression 
[9, 10]. As virotherapy based on CAR-utilizing vectors may 
be suboptimal for efficient tumor-targeting, evaluation of 
less common Ad types with alternative receptor tropisms is 
warranted.
Systemic cancer virotherapy using Ad5-based 
vectors is hampered by binding to host blood cells, pre-
existing anti-viral neutralizing antibodies (nAbs) and 
other proteins in the circulating blood. This results in rapid 
vector elimination and/or toxic adverse effects (reviewed 
in [2]). A recent epidemiological study with approximately 
1900 participants from eight geographical locations 
reported the prevalence of anti-Ad5 nAbs to be highest 
in Thailand (94 %), with overall prevalence of anti-Ad5 
nAbs being 85 % and lowest for HAdV-D36 (46 %) [11]. 
Species D Ads are appealing candidates as they have low 
seroprevalence, including in North and South American, 
sub-Saharan African and Southeast Asian populations 
[12, 13]. In this study Ad5 was pseudotyped with a fiber 
knob domain from HAdV-D48 (Ad48), generating a novel 
vector Ad5/kn48. The receptor usage of this vector was 
evaluated via in vitro competitive inhibition assays.
The limitations encountered with systemic delivery 
can be mitigated by local intratumoral or -cavity delivery 
of virotherapies. Therefore, we and others [14, 15] are 
developing viral vectors suitable for local intraperitoneal 
(i.p.) treatment of advanced ovarian cancer. The build-up 
of malignant ovarian ascites is an indicator of peritoneal 
metastases and poor prognosis. Ovarian ascites has a 
complex composition of various cell types and soluble 
proteins (reviewed in [16]), including high levels of anti-Ad5 
nAbs that inactivate Ad5-based therapeutic vectors [17–20]. 
The fiber has been suggested to be the primary target for 
nAbs residing in ovarian ascites [17]. We therefore reasoned 
that evasion of pre-existing humoral anti-viral immunity in 
ovarian cancer patients might be facilitated by modifying our 
fiber-pseudotyped vector Ad5/kn48.
The epithelial-specific αvβ6 integrin is absent 
in healthy adult tissues [21, 22] but over-expressed in 
various cancer types, including ovarian cancer [23, 24]. 
Importantly, up-regulation of αvβ6 integrin has been 
suggested to correlate with disease progression [22, 25, 
26]. We proposed to enhance cancer-selectivity using 
a previously-described 20-amino acid (aa) peptide, 
NAVPNLRGDLQVLAQKVART (A20) from foot-and-
mouth disease virus (FMDV) VP1 capsid protein with 
native affinity to αvβ6 integrin [27]. A20 was genetically 
engineered into the HI loop of the Ad5 fiber knob domain 
(Ad5.HI.A20) [28], in CAR-binding ablated KO1 
background [29] (Ad5.KO1.A20), and into the DG loop in 
the novel Ad5/kn48 vector (Ad5/kn48.DG.A20). The A20 
viruses were assessed for transduction efficiency in αvβ6-
expressing cancer cell lines. Ovarian ascites is a valuable 
source of primary epithelial ovarian cancer (EOC) cells 
that can be cultured [30, 31] for ex vivo evaluation 
of novel virotherapies [16]. Freshly-isolated clinical 
ovarian ascites-derived EOC cells from two donors were 
assessed with a view to designing improved oncolytic 
Ad vectors for i.p. treatment of advanced ovarian cancer. 
The combination of Ad5 capsid pseudotyping and αvβ6-
targeting presents a promising personalized medicine 
approach for local vector delivery.
RESULTS
Recombinant vectors
Four Ad5-based (+/− CAR binding/A20 peptide) 
and two chimeric Ad5/kn48 (+/− A20 peptide) vectors 
were engineered by homologous AdZ recombineering 
[33]. Viruses were successfully produced to high titers in 
T-REx-293 cells (Figure 1A), and fiber integrity verified 
by Western blotting using anti-Ad fiber antibody 4D2 
(Figure 1B). Sequence alignment of the knob domains 
revealed Ad48 knob to share three out of four key CAR-
binding residues with Ad5, including the two residues 
central for ablation of CAR-binding (KO1) (Figure 
1C). Incorporation of A20 peptide into the CD, HI or IJ 
loops of Ad5/kn48 was found to be incompatible with 
production of infectious virus (data not shown), while A20 
insertion into the DG loop (Ad5/kn48.DG.A20) resulted 
in a functional virus. A panel of cell lines and two ovarian 
ascites-derived primary cultures were selected for in vitro 
and ex vivo transduction assays, based on their varying 
CAR and αvβ6 expression profiles in flow cytometry 
analysis (Figure 1D).
A20 peptide increased transduction in  
αvβ6-positive cancer cells
All CAR-binding viruses were shown to efficiently 
transduce CHO-CAR (CARhigh/αvβ6neg) but not the 
control CHO-K1 (CARneg) cells (p < 0.001), whilst KO1 
mutation successfully ablated transduction (Figure 2A) 
as demonstrated previously [20]. These data strongly 
suggested the involvement of CAR receptor in the cellular 
transduction for the Ad48 fiber knob protein. BT-20 
breast carcinoma cells (CARlow/αvβ6high) were used as a 
αvβ6-positive control cell line. Ad5/kn48-pseudotyping 
resulted in similar level of transduction to that seen 
with the unmodified Ad5.Luc in BT-20 cells (Figure 2B; 
p = 0.9978). Conversely, transduction of the A20-modified 
viruses Ad5.HI.A20, Ad5.KO1.HI.A20 and Ad5/kn48.
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DG.A20 increased by ~ 160-, 270- and 180-fold relative 
to Ad5.Luc (Figure 2B; p = 0.0138, 0.0002 and 0.0068, 
respectively).
Variable transduction patterns were observed in 
freshly-isolated primary EOC cultures (Figure 2C-2D), 
consistent with their differing levels of receptor expression. 
The pattern seen in EOC3 cells (CARmed/αvβ6med) was similar 
to CARhigh CHO-CAR cells (Figure 2A), with significantly 
lower levels of transduction for all viruses as compared to 
Ad5.Luc (Figure 2C; p < 0.0001). Importantly, transduction 
in EOC4 cells (Figure 2D; CARmed/αvβ6high) was similar to 
the transduction pattern observed in BT-20 cells (Figure 2B), 
showing significant increase in transduction for all A20-
modified vectors as compared to Ad5.Luc (p < 0.0001). A20 
incorporation increased Ad5.HI.A20, Ad5.KO1.HI.A20 and 
Ad5/kn48.DG.A20 transduction in EOC4 cells by 68-, 58- 
and 16-fold as compared to Ad5.Luc (Figure 2D; p < 0.0001, 
< 0.0001 and 0.0041, respectively).
Ad5/kn48 utilized CAR for cell entry
Competition inhibition assays were performed in 
CHO-CAR (CARhigh) cells to assess the receptor usage 
of the knob-pseudotyped viruses (Figure 3A-3C). Ad5.
Luc was confirmed to utilize CAR for cell entry (Figure 
3A), as transduction was inhibited by pre-blocking the 
CAR receptor with kn5 protein (p = 0.0353), while CAR-
binding ablated control kn5.CAR– protein had no effect on 
transduction efficiency in CHO-CAR cells (p = 0.5646). No 
inhibition of Ad5.KO1 transduction by kn5 or kn5.CAR– (p 
= 0.9743 and 0.2342, respectively) was observed. Cell entry 
of Ad5.Luc and Ad5/kn48 via CAR was further assessed 
in dose-response assays. Significant reduction in Ad5.Luc 
transduction was observed (Figure 3B) at concentrations 
100, 10 and 1 μg of kn5 protein/105 cells (p = 0.0003, 0.0003 
and 0.0010, respectively). Similarly efficient inhibition 
was achieved for Ad5/kn48 at equal concentrations of 
kn5 (Figure 3C; p < 0.0001 at all three doses). We further 
assessed the 50 % inhibitory concentration (IC50) of kn48 
and found it to be ~ 1000-fold higher than that of kn5 
(Figure S2A), suggesting an affinity to CAR lower than kn5.
A20-modified virus transduction was αvβ6 
integrin-mediated
Successful binding to αvβ6 integrin was confirmed 
for Ad5.HI.A20, Ad5.KO1.HI.A20 and Ad5/kn48.DG.A20 
vectors in competition inhibition assays in BT-20 (αvβ6high) 
cells (Figure 3D). Ad5.Luc transduction was not significantly 
inhibited by any of the blocking agents as compared to ‘virus 
Figure 1: Generated vectors, cell line and primary epithelial ovarian cancer (EOC) cell phenotyping. A. Vectors +/− 
αvβ6-targeting peptide (A20) in different knob loops (+/− CAR binding) were generated by AdZ recombineering [33], propagated into high 
titers and titrated by microBCA assay (1 μg = 4 × 109 virus particles (vp)) [67]. B. Fiber integrity was confirmed on a Western blot using 
anti-Ad fiber antibody 4D2 (1:2000) with binding to residues (aa 1–17) outside those subject to modification; 1 × 1010 vp/lane. C. Ad5 and 
Ad48 fiber knob alignment: red boxes, CAR-binding sites [3]; green box, 13-aa deletion; black labels, A20 insertion sites/knob loops. D. 
Receptor expression profile of Chinese Hamster Ovary hamster ovarian (CHO-K1), CHO expressing CAR (CHO-CAR), CHO expressing 
CD46 (CHO-BC1), breast carcinoma (BT-20) cell lines and primary EOC cells from patients 3 and 4 were assessed by flow cytometry 
(normal mouse IgG, sc-2025; anti-CAR, Rcmb; anti-αvβ6, 10D5) and data analyzed on BD Accuri C6 software. CAR, human coxsackie 
and adenovirus receptor; KO1 mutation, CAR-binding ablation (S408E, P409A) [29]; A20 peptide, NAVPNLRGDLQVLAQKVART; vp/
mL, virus particles/mL.
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only’ conditions (p = 0.4806). Anti-αvβ6 antibody and kn48.
DG.A20 significantly inhibited both Ad5.HI.A20 and Ad5.
KO1.HI.A20 transduction (p < 0.0001 for all). Ad5/kn48 
vector was inhibited by kn48.DG.A20 protein only (p = 
0.0001). Importantly, Ad5/kn48.DG.A20 transduction was 
significantly inhibited by both anti-αvβ6 antibody and kn48.
DG.A20 protein (p = 0.0213 and 0.0059, respectively).
Ad5/kn48 did not use CD46 as its primary 
receptor
Species D Ads have previously been suggested 
to utilize CD46 as their primary entry receptor [12, 41]. 
However, fiber knob alignment showed CD46-binding 
residues [42] to be absent in the Ad48 knob domain (Figure 
4A). As BT-20 cells and the primary EOC cells express 
high levels of CD46 (Figure 4B), competition inhibition 
assays were performed in CHO-BC1 (CARneg/CD46high) 
cells using relevant CD46-utilizing control viruses to 
further assess the potential involvement of CD46 in 
Ad48 cell entry (Figure 4C). As expected, there were no 
differences in cell transduction in the CD46neg control cell 
line CHO-K1 for Ad5.Luc or Ad5/kn48 as compared to 
‘virus only’ conditions (Fig. 4C, top panel; (p = 0.1568 and 
0.2231, respectively). Similarly, anti-CD46 antibody did 
not inhibit transduction of these viruses in CHO-BC1 cells 
(p = 0.6382 and 0.2307, respectively), and no inhibition of 
CD46 detection was observed by flow cytometry following 
pre-incubation of cells with either kn48 or the CAR-binding 
kn5 protein (Figure S2B). Conversely, CD46-mediated 
entry of Ad5/F35 control vector [35, 36] into CHO-BC1 
cells was completely inhibited by anti-CD46 antibody (Fig. 
4C, bottom panel; (p = 0.001), with no significant inhibition 
observed in CHO-K1 cells (p = 0.3883).
A20 insertion enabled efficient transduction in 
the presence of neutralizing ovarian ascites
We [20] and others [17–19] have previously 
demonstrated that ascites contains high levels of nAbs that 
efficiently neutralize Ad5 vectors. To evaluate the effect of 
knob-pseudotyping and A20 insertion on protection from 
Figure 2: Vector transduction in αvβ6 integrin-expressing cancer cells. A. Control cell lines: Chinese Hamster cells (CHO-K1 
and CHO-CAR; n = 3); p values by two-tailed unpaired t test, B. Breast carcinoma (BT-20) cells in triplicate (n = 3), C. Ascites-derived 
epithelial ovarian cancer (EOC) cells from patient 3 in triplicate (n = 3) and D. EOC cells from patient 4 in duplicate (n = 2) were infected 
with 5000 virus particles/cell for 3 h, luciferase activity measured 48 h later and relative light units normalized to total cellular protein 
(RLU/mg). Data are representative of minimum of two independent experiments ± SD. Statistical significance shown as relative to Ad5.Luc 
using Dunnett’s multiple comparisons test; adjusted p: ns > 0.05, * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.
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pre-existing nAbs, transduction assays were performed 
in the presence of increasing concentrations of highly 
neutralizing cell-free ascites. Ascites from donor 1 was the 
most efficient at neutralizing Ad5.Luc (Figure S3) and was 
used in all neutralization assays. Efficient transduction was 
maintained for all αvβ6-targeted vectors in BT-20 cells 
(αvβ6high) in the neutralizing conditions, in contrast with 
the vectors with no available entry receptor (Figure 5A; 
Table S2A). To demonstrate the clinical scenario, virus 
transduction was assessed in primary ex vivo cultures 
EOC3 (αvβ6med) and EOC4 (αvβ6high) (Figure 5B-5C). 
In EOC3 cells, Ad5.Luc, Ad5.HI.A20 and Ad5/kn48.
DG.A20 were the only vectors to resist neutralization in 
the presence of 2.5 and 5 % ascites, while all vectors were 
completely neutralized at higher ascites concentrations 
(Figure 5B; Table S2B). Conversely, all αvβ6-targeted 
vectors transduced EOC4 cells at a greatly increased 
efficiency compared to Ad5.Luc (Table S2C) at up to 20 % 
ascites (Figure 5C), showing transduction patterns similar 
to that in the αvβ6high BT-20 cells (Figure 5A).
DISCUSSION
Recent positive results from the OPTiM phase III 
clinical trial of talimogene laherparepvec (T-VEC) [43] 
demonstrate that adjunctive oncolytic virotherapies are 
beginning to gain ground among anti-cancer therapies. 
The oncolytic herpes simplex virus type 1-based T-VEC 
showed improved durable response rate (16 % vs. 2 %) 
compared to the control arm (granulocyte-macrophage 
Figure 3: Evaluation of coxsackie and adenovirus receptor (CAR) and αvβ6 integrin receptor usage. Cells were pre-
blocked with soluble 6 x His-tagged Ad5 knob (kn5), Ad5 knob with ablated CAR-binding (kn5.CAR–), Ad48 knob with αvβ6-targeting 
peptide (A20) in DG loop (kn48.DG.A20) proteins (10 μg/105 cells), normal mouse control IgG (10 μg/ml) or anti-αvβ6 antibody 10D5 (10 
μg/ml) for 30 min on ice. Viruses were added at 5000 virus particles/cell for 1 h on ice, luciferase activity quantified 48 h later and relative 
light units normalized to total cellular protein (RLU/mg). A. CAR-binding competition inhibition assay in Chinese Hamster Ovary cells 
expressing CAR (CHO-CAR) in triplicate (n = 3). B-C. Dose-response CAR-binding competition inhibition assay in CHO-CAR cells, 
pre-blocking with kn5 protein at 100–0.001 μg/105 cells in quadruplicate (n = 4). D. αvβ6 integrin competition inhibition assay in breast 
carcinoma (BT-20) cells. Data are representative of a minimum of two independent experiments in triplicate (n = 3), ± SD. Statistical 
significance shown as relative to ‘virus only’ conditions for each vector using Dunnett’s multiple comparisons test; adjusted p: ns > 0.05, * 
< 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.
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colony-stimulating factor, GM-CSF), and an improved 
33.4 % 5-year overall survival [44]. T-VEC was licensed 
by the U.S. FDA in October 2015 and by EMA in 
December 2015 as the first oncolytic immunotherapeutic 
(Imlygic) in Europe for the treatment of metastatic 
melanoma [45]. Over a decade ago, the first oncolytic, 
conditionally-replicative Ad (CRAd) ‘H101’ was 
approved in China for combination therapies of head and 
neck carcinomas [46], and is now clinically available. 
Phase I/II clinical trials are currently ongoing for the 
treatment of advanced colorectal and other solid tumors 
with enadenotucirev (formerly ColoAd1), a chimeric 
Ad11p/Ad3 vector that has shown high selectivity, potent 
cancer-killing [47] and protection from anti-Ad humoral 
immunity [48].
Efficient systemic delivery of virotherapies is 
the long-term goal for metastatic cancer treatment but 
remains problematic due to toxicity-inducing ’off-target’ 
Figure 4: Evaluation of CD46 receptor usage. A. Ad5, Ad48 and Ad35 fiber knob alignment: red boxes, coxsackie and adenovirus 
receptor (CAR)-binding sites [3]; green box, 13-aa deletion; black labels, A20 insertion sites/knob loops; purple boxes, CD46-binding sites 
[42]. B. CD46 receptor expression was assessed in Chinese Hamster Ovary (CHO-K1), CHO cells expressing CAR (CHO-CAR), CHO 
expressing CD46 (CHO-BC1), breast carcinoma (BT-20) cell lines and ascites-derived primary ovarian epithelial cancer (EOC) cells from a 
donor 3 (EOC3) and donor 4 (EOC4) by flow cytometry (normal mouse IgG, sc-2025; anti-CAR, Rcmb; anti-CD46, MEM-258). Data was 
analyzed on BD Accuri C6 software. Competition inhibition assay in CHO-K1 and CHO-BC1 cells using C. luciferase (Luc) top panel and 
β-Gal-expressing viruses bottom panel. Cells were pre-incubated with normal mouse control IgG (10 μg/ml) or anti-CD46 clone MEM-258 
(10 μg/ml) for 30 min on ice and infected with 5000 viral particles/cell for 1 h on ice. Luciferase/β-galactosidase (β-Gal) expression was 
measured 48 h post-infection and relative light units were normalized to total cellular protein (RLU/mg). Data shown are representative of 
a minimum of two independent experiments in triplicate (n = 3), ± SD. Statistical significance shown as relative to ‘virus only’ conditions 
using Dunnett’s multiple comparisons test; adjusted p: ns > 0.05, * < 0.05, ** < 0.01, *** < 0.001.
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binding (reviewed in [2]). KO1 mutation [20, 29] presents 
a feasible strategy for abolishing binding to CAR that is 
ubiquitously expressed in healthy tissues but suppressed 
on various tumor types [9, 10]. Localized, i.p. treatment 
of ovarian cancer metastases would circumvent systemic 
interactions but therapeutic efficacy of Ad5-based 
vectors is severely hampered by high prevalence of anti-
Ad5 nAbs in the ascites [17–20]. Ascites-resident nAbs 
seem to be primarily anti-fiber [17], which is why fiber 
modification by heterologous peptide incorporation and/or 
pseudotyping may protect from neutralization (reviewed 
in [49]). Tropism-modified Ad5 vectors with peptide-
engineered fibers have previously showed improved in 
vitro transduction in the presence of neutralizing ascites 
[17, 20]. An alternative strategy to ablate native Ad5 
tropisms is via chemical modification the capsid with 
hydrophilic polymers such as poly(N-(2-hydroxypropyl)
methacrylamide) (pHPMA). Using this approach it has 
been possible to improve tumor-selectivity in i.p. ovarian 
cancer models via subsequent attachment of epidermal 
growth factor receptor (EGFR) [15, 50]. However, clinical 
efficacy of chemically-coated Ads may be limited, since 
chemical modification and targeting ligands are not 
heritable by the virus progeny.
Species D Ads present an appealing alternative to 
Ad5-based vectors due to their low seroprevalence [11, 
12], and alternative tissue tropisms [51–54]. Intriguingly, 
Ad48 has shown resistance to pre-existing anti-Ad5 nAbs 
[55], greater replication efficiency and oncolytic potency 
in B cell cancers compared to Ad5 [56]. In this study, we 
have shown that three out of four amino acids central for 
Ad5 CAR binding [57] are conserved in the Ad48 knob 
domain (Figure 1C), thus supporting the finding that Ad5/
kn48 vector utilizes CAR for cell entry (Figure 3C). Future 
modifications may therefore include the introduction of 
KO1 mutation to abolish CAR-binding. Species D Ads 
have been previously suggested to utilize CD46 as their 
primary entry receptor [12, 41, 54]. This observation was 
not supported here as CD46 was found to be non-essential 
for cell entry (Figure 4C and S2B). However the lower 
Figure 5: Vector neutralization by ovarian ascites. A. Breast cancer (BT-20) cells, B. ascites-derived primary ovarian epithelial 
ovarian cancer (EOC) cells from donors 3 and C. 4 were incubated with 2-fold dilutions of highly-neutralizing cell-free ascites (Fig. S3, 
donor 1) for 30 min at 37°C, and infected at 200 000 virus particles/cell for 2 h at 37°C. Luciferase activity was measured 48 h later and 
relative light units normalized to total cellular protein (RLU/mg). Data are representative of a minimum of two independent experiments in 
duplicate (n = 2). ‘virus’, virus only in ascites- and serum-free conditions.
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affinity of kn48 for CAR (Figure S2A) could imply the 
involvement of additional co-receptors that remain to be 
determined in prospective studies.
Poor tumor-specificity remains one of the key hurdles 
in Ad vector design. This may be overcome by genetic 
insertion of peptide ligands for targeting tumor cell-specific 
receptors. αvβ6 integrin is undetectable in normal adult 
tissues [21, 22] but up-regulated in many cancer types, 
such as ovarian [23], breast [58], colon [59], prostate cancer 
[60] and cancer of the oral cavity [61], as well as squamous 
carcinomas of the cervix, skin, esophagus, and head and 
neck [24]. Its cancer-specific expression and established role 
as a prognostic indicator [22, 25, 26] make it an appealing 
target for anti-cancer vectors. A20, originally derived from 
VP1 capsid protein of FMDV [27], natively binds αvβ6 
integrin with high affinity, and has previously been utilized 
for Ad5 tumor-targeting in vivo [28].
A20 peptide was inserted into the Ad5 fiber knob 
HI loop [28], and CD, DG, HI and IJ loops within Ad5/
kn48 by homologous recombineering [33]. Predictive 3D 
models [39] showed A20 in Ad48 DG and HI loops in 
a favorably-exposed conformation for receptor binding 
(Figure S1). A20 insertion into DG and HI loops of 
recombinant kn48 protein has previously been shown to 
impair fiber trimerization, suggesting these sites to be 
suboptimal [34]. Conversely, in this study DG was the 
only loop that tolerated A20 insertion in combination 
with a 13-aa deletion, allowing functional Ad5/kn48 virus 
production (Figure 1A-1B). A20 behaved differently in 
the context of the whole virion, likely due to unpredicted 
steric hindrance and conformational changes. Ad5 fiber 
knob is well-characterized for re-targeting strategies 
[62–64], with knob loops HI [65], CD and IJ [66] 
known to tolerate insertion of targeting peptide moieties 
without compromised viral functionality. However, direct 
comparison of Ad5 and Ad48 is problematic as they 
belong to different subgroups (48 % fiber knob homology).
Incorporation of A20 rendered αvβ6high virus-
resistant cancer cell lines and αvβ6high primary EOC ex 
vivo cultures susceptible to transduction and resulted 
in improved re-targeting relative to the CAR-utilizing 
parent vector Ad5.Luc (Figure 2). Competition inhibition 
assays utilizing function-blocking agents demonstrated 
that cell transduction was indeed CAR- and/or αvβ6 
integrin-mediated (Figure 3). The observed differences 
in transduction efficiency between the primary cultures 
EOC3 and EOC4 (Figure 2) are consistent with well-
recognized inter-patient heterogeneity of tumors. An 
estimated 33 % of ovarian cancers express αvβ6 integrin 
[24], and therefore stratification of patients may be 
required for a personalized virotherapy approach.
Ascites-resident anti-Ad5 nAbs [17–20] can severely 
hinder i.p. ovarian cancer virotherapies. Intriguingly, all 
αvβ6 integrin-targeted vectors demonstrated efficient 
transduction in αvβ6high breast cancer cell line and primary 
αvβ6high EOC ex vivo cultures in the presence of highly 
neutralizing clinical ascitic fluid (Figure 5A, 5C). The 
protective effect was less pronounced in primary EOC3 
cells (Figure 5B), likely due to lower levels of cellular 
target receptors. A20 not only enabled cell transduction via 
a non-native, cancer-specific pathway but may also have 
contributed to the occlusion of neutralizing epitopes within 
the fiber knob. Adenoviral cancer-targeting via αvβ6 
integrin merits further investigation and manipulation for 
oncolytic purposes. Local administration of adjunctive 
virotherapies has vast potential for fighting aggressive, 
relapsed forms of ovarian cancer.
MATERIALS AND METHODS
Cell lines, primary cell culture and flow 
cytometry
All cell lines were originally obtained from 
American Type Culture Collection (ATCC). T-REx-293 
Human Embryonic Kidney cells were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM), A549 lung carcinoma 
cells in Roswell Park Memorial Institute (RPMI) 1640, BT-
20 breast carcinoma cells in Eagle’s Minimum Essential 
Medium (EMEM, α modification), Chinese Hamster 
Ovary cells (CHO-K1), CHO cells expressing CAR (CHO-
CAR) and CHO cells expressing CD46 receptor isoform 
BC1 [32] (CHO-BC1) in DMEM: Nutrient Mixture F12. 
All media were supplemented with 4 mM L-Glutamine, 
100 U/mL penicillin, 100 μg/mL streptomycin and 10 % 
fetal calf serum (except 20 % for BT-20), and cells grown 
at 37°C in a humidified atmosphere with 5 % CO2. All 
reagents were purchased from Gibco (Paisley, UK) or 
Sigma Aldrich (Gillingham, UK).
Permission for the collection and cultivation of 
primary EOC cells from ascites was granted through a 
Wales Cancer Bank application for biomaterials (reference 
WCB 14/004). All patients gave written informed consent 
prior to collection. Samples from two donors undergoing 
treatment at Velindre Cancer Centre, Cardiff were 
anonymized – EOC3 was from a patient with no prior 
history of chemotherapy and EOC4 from a patient with 
relapsed, platinum-resistant disease. Cells were collected 
by centrifugation of 500 mL ascites, processed and sub-
cultured as described previously [20].
Receptor expression profiles were assessed by 
flow cytometry. Cells were incubated with normal mouse 
IgG control sc-2025 (1:200; Santa Cruz Biotechnology, 
Heidelberg, Germany), mouse anti-CAR clone Rcmb 
(1:500; Millipore, Watford, UK), mouse anti-αvβ6 clone 
10D5 (1:100; Millipore, Middlesex, UK) or mouse anti-
CD46 clone MEM-258 (1:100; Abcam, Cambridge, UK) in 
triplicate. 10 000–20 000 events were recorded in channel 
FL-4 and data assessed on BD Accuri C6 (BD Biosciences) 
flow cytometer. The flow cytometry data were analyzed 
using BD Accuri C6 software version 1.0.264.21 (Becton 
Dickinson, USA) as described previously [20].
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Recombinant adenoviruses
Pseudotyped Ad5/Ad48 vectors were generated by 
AdZ homologous recombineering as described previously 
[33]. Viral genomes were based on luciferase (Luc)-
expressing replication-deficient (ΔE1/ΔE3) (Ad5.Luc) and 
introduced modifications were verified by sequencing [20]. 
A20 insertion sites in Ad5 [28] and Ad48 knob loops [34] 
were selected based on conformational compatibility for 
receptor binding (Figure S1). Ad48 knob sequences were 
PCR-amplified from previously generated pQE30knob48 
plasmids [34] (primers, Table S1) and inserted into Ad5.
Luc fiber knob (Ad5 fiber sequence before TLW hinge 
region (aa 400–402), Ad48 fiber afterwards). To generate 
Ad5.HI.A20, A20 sequence was amplified from the 
previously engineered pQE30knob48.DGΔ13aa.A20 
plasmid [34] by PCR and inserted into the Ad5.Luc fiber 
knob HI loop (aa 546/547). The Ad5/kn48.A20 has a 13-aa 
deletion in the fiber knob prior to the site of A20 insertion 
[34] (aa 297–311) (Figure 1C). CAR-binding ablating 
mutation KO1 [29] was introduced into the fiber knob 
AB loop (S408E, P409A). All vectors were produced, 
purified and characterized as described previously [20]. 
The β-galactosidase (β-Gal) expressing control vectors 
Ad5.β-Gal and Ad5 with HAdV-B35 fiber (Ad5/F35) [35, 
36] were a kind gift from Prof. Andrew Baker, University 
of Glasgow, UK.
Transduction, neutralization and competition 
inhibition assays
Transduction, competition inhibition and 
neutralization assays were performed using the Luciferase 
Assay System kit (Promega UK Ltd, Southampton, UK) 
for the Luc-expressing viruses as described previously 
[20]. For quantification of the β-Gal expressing 
control virus Ad5.β-Gal and Ad5/F35 transduction, 
β-Gal expression was measured using Galacto-Light 
Plus System according to manufacturer’s instructions 
(Applied Biosystems, Bedford, Massachusetts, USA). 
Luminescence was measured on a multimode plate 
reader (FLUOstar Omega, BMG Labtech, Aylesbury, 
UK). Values were expressed as relative light units (RLU) 
and normalized for total cellular protein (RLU/mg), as 
described previously [20].
For CAR competition inhibition assays, soluble, 
recombinant 6 x His-tagged knob proteins were produced 
as described previously [28, 34]; wild type Ad5 knob 
(kn5), Ad5 knob with a CAR-binding ablation mutation 
Y477A in the DE loop [37] (kn5.CAR–), wild type Ad48 
knob (kn48) and Ad48 knob with a 13-aa deletion and 
A20 peptide in the DG loop (kn48.DG.A20). Cells were 
pre-incubated with the soluble knob proteins (10 μg/105 
cells), function-blocking anti-αvβ6 antibody clone 10D5 
(10 μg/ml), function-blocking anti-CD46 clone MEM-258 
(10 μg/ml) or normal anti-mouse control IgG (10 μg/ml) 
for 30 min on ice and viruses added for further 1 h on 
ice. In dose-response assays, cells were pre-blocked with 
0.001–100 μg of kn5 protein/105 cells. Flow cytometry 
was used to determine the ability of recombinant kn5 
and kn48 proteins (0.0001–100 μg/105 cells) to bind and 
competitively inhibit anti-CAR (RmcB) (Figure S2A) and 
anti-CD46 (MEM-258) antibody binding (Figure S2B) 
as described previously [28, 34]. Cell-free ascitic fluids 
from five donors were tested on A549 lung carcinoma 
cells (CARhigh) for selection of the most neutralizing 
sample (Figure S3). This fluid (donor 1) was used in all 
neutralization assays.
Sequence alignments and predictive structural 
modelling
Ad5 (GenPept: AAP31231.1), Ad48 (GenPept: 
ABO61306.1) and Ad35 (GenPept: AP_000601.1) fiber 
sequences were aligned in BioEdit [38] version 7.2.5 
using the ClustalW Multiple Alignment command. A20-
modified knob domains were modelled in predictive 
online 3D modelling software SWISS-MODEL [39] 
(Biozentrum, Basel, Switzerland) on automated mode and 
saved as Protein Data Bank (PDB) files for further editing. 
Ad5 knob models were based on PDB structure 1KNB and 
Ad48 knobs based on the closest homology (64 %) HAdV-
D19p structure (PDB ID: 1UXB) as crystallization data for 
Ad48 is not available. Molecular graphics and analyses 
were performed using the UCSF Chimera package [40] 
version 1.10.2 (Resource for Biocomputing, Visualization, 
and Informatics; University of California, San Francisco, 
USA).
Statistical analyses
Two-tailed unpaired t test was used for analysis in 
Figure 2A. One-way ANOVA with Dunnett’s multiple 
comparisons post hoc test was used in all other assays. 
All analyses and graphs were created in GraphPad Prism 
version 6.03 (GraphPad Software Inc., La Jolla, CA, 
USA).
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